EP-1351: Developing a prostate decision aid tool considering patients and clinicians decisional needs  by Berlanga, A.J. et al.
ESTRO 35 2016                                                                                                                                                    S631 
________________________________________________________________________________ 
Results: Median follow and median age were 75 m (range: 
60-99) and 74 y (57-84) respectively, while median Gleason 
score( GS) was 6 (3-10):GS<7: 75; GS=7: 39; GS>7: 13 ; 
missing:2. 73 pts were staged as T1, 46 as T2: 6 as T3; and 
for 3 pts the stage was unclear (Tx). The median initial Psa ( 
iPsa) was 7.8 (1.2-826). The 75-m bRFS was 92.5% (LR: 94.2%; 
IR: 96.9%; HR: 84.5%); OS was 94.6% ( LR:95.9%; IR: 95.8%; 
HR: 91.1%) and CSS was 97.4% (LR: 100%;IR:94.5%;HR: 97.1%). 
AD and class risk were not correlated with bRFS/OS/CSS. The 
incidence of G3 toxicity was around 6% with drastically 
reduction of the prevalence at the last follow-up for both 
≥G2 and ≥G3 toxicities indicating that symptoms were 
recovered in most patients. 
 
Conclusion: The combination of pelvic LN irradiation and 
high dose to the prostate, (EQD2=88Gy) delivered with daily 
image-guided, intensity-modulated, moderate 
hypofractionation resulted in an excellent 75-m outcome, 
even in IR/HR patients. This encouraging result seems to be 
without correlation with AD considering the long time 
elapsed between the end of the AD and the last follow up of 
pts. The toxicity profile was acceptable  
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Purpose or Objective: To compare clinical results of 
adjuvant and salvage radiotherapy after radical 
prostatectomy for prostate cancer and to determinate 
prognostic factors of biochemical relapse free survival 
(BRFS).  
 
Material and Methods: 302 patients were treated at our 
institution over a 12-year period. Overall survival and 
biochemical-relapse free survival were analized using Kaplan-
Meier and multivariate Cox regression analysis was used to 
assess differences between groups. 
 
Results: Mean age at diagnosis was 65 years (42-80). All 
patients underwent radical prostatectomy combined with 
pelvic lymphadenectomy in 47.1% of cases. Neoadjuvant 
androgen deprivation before surgery was given to 36.5% . 
Mean pre-RT PSA of 0.46ng/ml (0-12.8 ng/ml). Adjuvant RT 
(ART) was performed in 113 patients and salvage RT (SRT) in 
183 (9 for local recurrence) and mean dosis to surgical bed 
was 70 Gy (60-76 Gy). The distribution of patients by pT 
stage was pT2a/b (30.3%), pT2c (35%), pT3 (29%) and pT4 
(2.3%). Upgrade in Gleason Score between transrectal biopsy 
and prostatectomy was experienced by 46.7% of patients. 
Positive surgical margins were reported in 56.5% of cases. 
Mean follow-up was 58.85 months (1-153 months). Overall 
survival at 5 and 10 years was 98.1% and 94.3%, respectively 
and BRFS at 5 and 10 years was 76.5% vs. 61.8%, respectively. 
The timing of RT (ART vs. SRT) and pre-RT PSA <0.5 ng/ml 
were significant predictors of longer BRFS.  
 
 
 
Conclusion: Postoperative radiation therapy provides 
excellent long-term overall survival results with an aceptable 
BRFS with pre-RT PSA <0.5 ng/ml and adjuvant radiotherapy 
as predictors of better outcomes. 
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Purpose or Objective: To facilitate shared decision making, 
we aim to develop a decision aid tool that helps prostate 
cancer patients to understand the benefits and side-effects 
of the treatments offered by their clinicians.  
The tool should follow the International Patient Decision Aid 
Standard, and therefore patient’s and doctor’s views on 
decisional needs must be considered. The tool should have a 
new slant on existing tools: it should personalize the 
information, guide patients to identify their preferences, and 
help doctors to understand patients’ preferences. 
 
Material and Methods: Patients and clinicians were 
interviewed to assess their decisional needs. A prototypical 
tool was developed. Its clarity and acceptability was 
evaluated by the technology acceptance questionnaire (5-
Likert scale). 
 
Results: Prostate cancer patients already treated (N=16) 
mentioned the need of visual and free of medical jargon 
information about prostate cancer, treatments, side-effects, 
and treatment experience. Medical specialists (N=8; radiation 
oncologists, urologists, nurses) mentioned the need of 
information about basic anatomy, contraindications, hospital 
specific figures, and psychological support. Results about 
comprehensibility of the prototypical tool showed that most 
the patients fully agree (69%) or agree (31%) that the 
prototypical tool provides clear information about 
treatments, their side-effects, the differences between 
treatments, and eases comparison. Likewise, most of the 
patients fully agree (69%) or agree (31%) on using the tool if 
it would became available, and will recommend it to others 
(67% fully agree; 33% agree).  
After considering the views of patients and medical 
specialists, the result is an alpha version of a web-decision 
aid tool for prostate cancer patients 
(http://www.treatmentchoice.info). The tool personalizes 
information for each patient. It assists patients to decide 
what their preferences regarding quality of life and 
treatment experience are, and to think how important are 
the side-effects for them. It provides a printed report of 
patients’ preferences to be using during consultation. Fig 
below gives an impression. 
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Conclusion: The alpha version of the tool is a first step 
towards its implementation in the clinical practice. The tool 
will be tested further by patients, to investigate whether it 
(a) influences the quality of the decision; (b) can be used 
without support. The tool is available in Dutch, English and 
Italian. Future efforts include the development of decision 
tools for other primary tumors. 
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Purpose or Objective: The increased use of magnetic 
resonance imaging (MRI) for radiotherapy (RT) target 
delineation has encouraged method development to enable 
the entire RT treatment planning workflow based on MRI 
only. Earlier we have presented a procedure for MRI only 
based treatment planning replacing planning CT in all phases 
of RT including simulation, target volume definition, dose 
calculation based on a pseudo-CT image set generated from 
MRI, and image guidance where comparison between MR or 
pseudo-CT reference set and MV/kV planar images or cone-
beam CT is performed. The method has been applied 
clinically for RT planning of localized prostate cancer since 
November, 2012. Here we present our early clinical 
experience. 
 
Material and Methods: We have followed n = 125 patients 
treated with MRI only procedure with serum prostate-specific 
antigen (PSA) at the beginning (baseline) and end of the RT 
course. As a reference, similar group of patients has been 
chosen where RT were planned with similar irradiation 
technique, margins, dosage (prostate 76 Gy in 2 Gy fractions, 
seminal vesicles 66 Gy in 2 Gy fractions) and image guidance 
method (gold seeds + daily kV/MV imaging), but where CT 
planning image set has been used as a primary data set in 
treatment planning and IGRT, and MRI images were 
registered to CT for target delineation. For the reference 
group, equal number of patients with additional antiandrogen 
therapy (n = 100) or RT only (n = 25) were chosen. 
 
Results: Mean PSA values for all the patient subgroups are 
presented in Table 1. The two methods show equal early 
response in PSA. No difference in early toxicity was noticed 
between the MRI only and CT+MRI groups. 
 
 
 
Conclusion: MRI only based RT treatment planning gave 
expected and equivalent results after RT compared with CT 
(MRI registered) based treatment planning procedure. Longer 
follow-up is needed to confirm the clinical equivalence 
related both to tumour response and normal tissue toxicity. 
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Purpose or Objective: On the basis of radiobiological studies 
suggesting a low α/β ratio for prostate adenocarcinoma, 
hypofractionation has been proposed to improve outcome in 
localized prostate cancer. STIP trial is a single center 
prospective phase I/II trial, with the aim of investigating 
feasibility and safety of moderate hypofractionation in low 
and intermediate risk (LR and IR) prostate cancer with Helical 
Tomotherapy (HT). We report early results in the first twelve 
recruited patients. 
 
Material and Methods: Inclusion criteria are: histologically 
confirmed adenocarcinoma, age ≥ 18  and ≤ 85 years, LR and 
IR according to NCCN, performance status (Karnofsky) ≥ 60, 
no clinical or radiological sign of metastasis, International 
Prostate Symptom Score (IPSS) ≤ 19, no previous cancer 
history.The addition of short-term Androgen Deprivation 
Therapy to radiation is prescribed for IR patients and 
performed for 6 months. CT/MR simulation and all treatment 
sessions were performed with empty rectum and comfortably 
full bladder. Clinical target volume (CTV) 1 comprised the 
prostate gland in 11 LR patients, CTV2 also included the 
seminal vesicles in one IR patient. Planning target volumes 
(PTV) 1 and 2 were defined, respectively, as CTV1 and 2 plus 
a 0.5 cm margin. Total doses of 60 Gy and 54 Gy were 
delivered, in 20 fractions, to PTV1 and 2, respectively. To 
compare CTVs and PTVs obtained with CT and MRI, these 
volumes were contoured on CT scans and then on the merged 
image sets. Before each fraction, daily megavoltage 
tomography (MCVT) was performed to reduce interfraction 
uncertainties. 
 
Results: Median follow-up was 12 months (range 3–20 
months). Mean dose to PTV1 was 60.15 Gy ( range 59.98-
60.27), mean dose to PTV2 was 54.65 Gy. According to CTCAE 
3.0 scale, acute G1 and G2 gastrointestinal toxicity occurred 
in 3 (25%) and 1 (8%) patients, respectively; no patients 
experienced G3 toxicity. G1 genitourinary toxicity occurred 
in 6 (50%) patients and no G2 or higher grade side effects 
were observed. According to the Expanded Prostate Cancer 
Index Composite (EPIC) questionnaire, urinary function 
declined 3 months post-treatment but it was similar to 
baseline at 12 months; bowel related quality of life remained 
stable during follow-up. IPSS remained similar to baseline for 
all patients. The contoured volume analysis showed that CTV 
and PTV based on MRI were always lower than CT based 
volumes (mean 38.07-87.10 vs 50.84-106). No patients 
experienced biochemical failure during follow-up. 
 
Conclusion: Our preliminary data support the safety of a 20-
fraction hypofractionated schedule delivered with HT in 
patients with localized prostate cancer. 
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Purpose or Objective: Carbon ion is characterized by unique 
physical and biological properties which is expected to be 
suitable to treat localized prostate cancer. In order to assess 
validate the feasibility and efficacy of carbon-ion 
radiotherapy for prostatic cancer, we synthesize and 
